In an era of unprecedented scientific breakthroughs and transformative technologies, the future of life sciences in India holds immense promise. Let us explore the transformative potential of Life Sciences with Zeon Lifesciences Ltd. as we strive to create a healthier and happier global community.
1. How do you see the future of Life Sciences in India?
Life Sciences in India has a promising future. Countries aboard are now looking at India to get their products manufactured. India has a strong pool of scientific talent, and the government is increasingly investing in research and development (R&D). The biopharma industry is also growing rapidly because of the country’s low cost of manufacturing, skilled workforce, and supportive government policies. The Life Sciences industry is being disrupted by new technologies such as artificial intelligence (AI), big data, and gene editing. These technologies will be used to develop new drugs and diagnostics that are more personalised and effective. The government, industry, and academia are increasingly collaborating to boost the Life Sciences sector in India. This collaboration is essential to accelerate innovation and translate research into commercial products.
2. What are the key ethical considerations companies think of when developing new technologies or products in the Life Sciences field?
By prioritising ethical considerations, companies can humanise their approach to technological advancements in the Life Sciences field, fostering a positive impact on society and the well-being of all individuals involved. These considerations revolve around ensuring the well-being and safety of human subjects during research or clinical trials. It’s crucial for companies to obtain clear and informed consent from participants before involving them in any studies. Companies should show genuine concern for the welfare of animals used in testing or research. Preserving intellectual property becomes essential as it enables companies to invest in crucial research and development efforts. Companies must be diligent in considering the potential risks and benefits. The goal is to develop safe, effective, and affordable solutions that positively impact people’s lives while adhering to relevant regulations.
3. What specific area or problem in Life Sciences does your company focus on, and why did you choose that particular area?
At Zeon Lifesciences Ltd., our focus lies in the vital areas of nutraceuticals, ayurvedic, herbal, immunity-boosters, phytoformulations, veterinary nutrition, medical nutrition, sports nutrition, health, and wellness products, and food ingredients. Our dedication to research and development drives us to constantly work towards creating new and innovative products. Moreover, we actively seek joint ventures and academic collaborations to expand our reach and effectiveness.
Founder & CMD
Zeon Lifesciences Limited
Our founder and CMD, Mr. Suresh Garg, is a true pioneer who envisioned the potential of the nutraceutical unit early on. He recognised the pressing need in the market and aspires to create a disease-free world through nutraceuticals. Nutraceuticals go beyond basic nutrition and have the power to prevent and manage chronic diseases. We firmly believe that by focusing on nutraceuticals and other areas, we can positively transform the lives of millions, contributing to a healthier and happier global community. Our vision to nurture lives with health and wellness products drives our unwavering commitment to cutting-edge research at Zeon Lifesciences Ltd.
4. What are the major challenges in the Life Sciences sector, and how does one overcome them?
In the dynamic world of life sciences, we encounter several significant challenges that call for thoughtful solutions. A few of them are escalating costs of research and development, navigating through regulatory compliances, prolonging the time to deliver life-changing innovations, increasing the complexity of diseases, and the rising cost of healthcare. Even in the face of these obstacles, there is hope. By adopting a collaborative approach, we can foster private-public partnerships that pool resources and expertise. Investing in research and development remains essential, and with added strong government support. Embracing new technologies will be crucial in finding innovative solutions to current obstacles. Moreover, a focus on personalised nutrition can yield transformative outcomes in patient care.
